ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
97 528,75
-0,23%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Adagene Inc (ADAG) Cours

Adagene Inc

Adagene Inc (ADAG)

NASDAQ
2,05
0,04
(1,99%)
Fermé 21 Décembre 10:00PM
Retardé de 15 minutes
2,05
0,00
(0,00%)
Après les heures de négociation: 11:16PM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
2,05
Prix Achat
1,84
Prix Vente
2,15
Volume échangé
36 918
1,89 Fourchette du Jour 2,0675
0,00 Plage de 52 semaines 0,00
Cap du marché
90,439M
Clôture Veille
2,01
Ouverture
2,04
Dernière Transaction
45
@
1.95
Dernière heure de transaction
Volume financier
US$ 73 414
VWAP
1,9886
Volume moyen (3 m)
-
Actions en circulation
44 116 671
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-4,77
Bénéfice par action (BPA)
-0,43
Chiffre d'affairess
21,59M
Bénéfice net
-18,95M

À propos de Adagene Inc

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reacti... Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Grand Cayman, Cym
Fondé
-
Adagene Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ADAG. Le dernier cours de clôture d'Adagene était de US$2,01. Au cours de la dernière année, les actions de Adagene ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Adagene compte actuellement 44 116 671 actions en circulation. La capitalisation boursière d'Adagene est de US$88,67 million. Adagene a un ratio cours/bénéfice (ratio PE) de -4.77.

ADAG Dernières nouvelles

Plus de nouvelles

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

07 Novembre 2024
Edgar (US Regulatory)

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

07 Novembre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

07 Novembre 2024
Edgar (US Regulatory)

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc

- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4...

07 Novembre 2024
GlobeNewswire Inc.

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies...

09 Octobre 2024
GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

24 Septembre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

16 Septembre 2024
Edgar (US Regulatory)

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC

- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg...

16 Septembre 2024
GlobeNewswire Inc.

Adagene to Participate in Investor Conferences in September

SAN DIEGO and SUZHOU, China, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and...

29 Août 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

25 Juillet 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

ADAG - Frequently Asked Questions (FAQ)

What is the current Adagene share price?
The current share price of Adagene is US$ 2,05
How many Adagene shares are in issue?
Adagene has 44 116 671 shares in issue
What is the market cap of Adagene?
The market capitalisation of Adagene is USD 88,67M
What is the 1 year trading range for Adagene share price?
Adagene has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Adagene?
The price to earnings ratio of Adagene is -4,77
What is the cash to sales ratio of Adagene?
The cash to sales ratio of Adagene is 4,19
What is the reporting currency for Adagene?
Adagene reports financial results in USD
What is the latest annual turnover for Adagene?
The latest annual turnover of Adagene is USD 21,59M
What is the latest annual profit for Adagene?
The latest annual profit of Adagene is USD -18,95M
What is the registered address of Adagene?
The registered address for Adagene is P. O. BOX 31119 GRAND PAVILION, HIBISCUS WAY, 802 WEST BAY ROAD, GRAND CAYMAN, KY1 - 1205
Which industry sector does Adagene operate in?
Adagene operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
121,03M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
78,06M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
34M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,94k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
121,95M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,91M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,75M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,94M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
9,27M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
6,25M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,32M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
305,1M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
292,16M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
287,21M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
277,63M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
ADAG
Adagene
LSE
BT.A
Bt
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés